Search results
Powerful overall survival data. IMPACT: PROVENGE has been clinically proven to extend life for certain men with mCRPC. In IMPACT, the double-blind, placebo-controlled trial that supported FDA approval of PROVENGE, men with mCRPC (N=512) were randomly assigned in a 2:1 ratio to receive either sipuleucel-T (n=341) or placebo (n=171).
29 lip 2010 · With a median follow-up of 34.1 months and complete survival follow-up data for 99% of patients, treatment with sipuleucel-T resulted in a 4.1-month improvement in median survival and an ...
Patients received intravenous (IV) sipuleucel-T (n = 341) or placebo (n = 171) at two-week intervals, for a total of three doses. At 36 months, a survival benefit of 4.1 months was noted with sipuleucel-T; median survival was 25.8 months with sipuleucel-T and 21.7 months with placebo.
4 wrz 2019 · PROCEED provides contemporary survival data for sipuleucel-T–treated men in a real-world setting of new life-prolonging agents, which will be useful in discussing treatment options with patients and in powering future trials with sipuleucel-T.
On this website, you can find information about PROVENGE survival data, mechanism of action, and safety profile. Where can I find an overview of PROVENGE for patients? A PROVENGE treatment brochure and video were created for men who are considering treatment with PROVENGE.
1 gru 2019 · PROCEED provides contemporary survival data for sipuleucel-T-treated men in a real-world setting of new life-prolonging agents, which will be useful in discussing treatment options with patients and in powering future trials with sipuleucel-T.
PROVENGE ® (sipuleucel-T) is a prescription medicine used to treat certain men with advanced prostate cancer. PROVENGE is an established cellular immunotherapy and is customized to each individual by using his own immune cells.
